Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection

Science Translational Medicine

Volumn 9, Issue 402, 2017, Pages

  Parsons, Matthew S ^a   Lloyd, Sarah B ^a   Lee, Wen Shi ^a   Kristensen, Anne B ^a   Amarasena, Thakshila ^a   Center, Rob J ^a,b   Keele, Brandon F ^c   Lifson, Jeffrey D ^c   La Branche, Celia C ^d   Montefiori, David ^d   Wine, Bruce D ^b   Hogarth, P Mark ^b   Swiderek, Kristine M ^e   Venturi, Vanessa ^f   Davenport, Miles P ^f   Kent, Stephen J ^a,g  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BURNET INSTITUTE   (Australia)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Theraclone Sciences Inc   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANIMAL; ANTIBODY PRODUCTION; HUMAN; IMMUNOLOGY; MACACA; MALE; PATHOGENICITY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; HUMANS; MACACA; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

EID: 85027403406     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf1483     Document Type: Article

References (63)

1. M. R. Gardner, L. M. Kattenhorn, H. R. Kondur, M. von Schaewen, T. Dorfman, J. J. Chiang, K. G. Haworth, J. M. Decker, M. D. Alpert, C. C. Bailey, E. S. Neale Jr., C. H. Fellinger, V. R. Joshi, S. P. Fuchs, J. M. Martinez-Navio, B. D. Quinlan, A. Y. Yao, H. Mouquet, J. Gorman, B. Zhang, P. Poignard, M. C. Nussenzweig, D. R. Burton, P. D. Kwong, M. Piatak Jr., J. D. Lifson, G. Gao, R. C. Desrosiers, D. T. Evans, B. H. Hahn, A. Ploss, P. M. Cannon, M. S. Seaman, M. Farzan, AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87-91 (2015).
2. A. J. Hessell, L. Hangartner, M. Hunter, C. E. G. Havenith, F. J. Beurskens, J. M. Bakker, C. M. S. Lanigan, G. Landucci, D. N. Forthal, P. W. H. I. Parren, P. A. Marx, D. R. Burton, Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
3. B. Moldt, E. G. Rakasz, N. Schultz, P.-Y. Chan-Hui, K. Swiderek, K. L. Weisgrau, S. M. Piaskowski, Z. Bergman, D. I. Watkins, P. Poignard, D. R. Burton, Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U.S.A. 109, 18921-18925 (2012).
4. P. W. H. I. Parren, P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, D. R. Burton, Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
5. R. S. Veazey, R. J. Shattock, M. Pope, J. C. Kirijan, J. Jones, Q. Hu, T. Ketas, P.A.Marx, P. J. Klasse, D. R. Burton, J. P. Moore, Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
6. C. Moog, N. Dereuddre-Bosquet, J.-L. Teillaud, M. E. Biedma, V. Holl, G. Van Ham, L. Heyndrickx, A. Van Dorsselaer, D. Katinger, B. Vcelar, S. Zolla-Pazner, I. Mangeot, C. Kelly, R. J. Shattock, R. Le Grand, Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 7, 46-56 (2014).
7. K. O. Saunders, L. Wang, M. G. Joyce, Z.-Y. Yang, A. B. Balazs, C. Cheng, S.-Y. Ko, W.-P. Kong, R. S. Rudicell, I. S. Georgiev, L. Duan, K. E. Foulds, M. Donaldson, L. Xu, S. D. Schmidt, J.-P. Todd, D. Baltimore, M. Roederer, A. T. Haase, P. D. Kwong, S. S. Rao, J. R. Mascola, G. J. Nabel, Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects non-human primates from mucosal simian-human immunodeficiency virus infection. J. Virol. 89, 8334-8345 (2015).
8. M. Veselinovic, C. P. Neff, L. R. Mulder, R. Akkina, Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432, 505-510 (2012).
9. B. F. Haynes, T. Bradley, Broadly neutralizing antibodies and the development of vaccines. JAMA 313, 2419-2420 (2015).
10. D. J. Anderson, J. A. Politch, A. M. Nadolski, C. D. Blaskewicz, J. Pudney, K. H. Mayer, Targeting Trojan Horse leukocytes for HIV prevention. AIDS 24, 163-187 (2010).
11. D. J. Anderson, E. J. Yunis, "Trojan Horse" leukocytes in AIDS. N. Engl. J. Med. 309, 984-985 (1983).
12. J. A. Levy, The transmission of AIDS: The case of the infected cell. JAMA 259, 3037-3038 (1988).
13. J. Ndirangu, J. Viljoen, R. M. Bland, S. Danaviah, C. Thorne, P. Van de Perre, M.-L. Newell, Cell-free (RNA) and cell-associated (DNA) HIV-1 and postnatal transmission through breastfeeding. PLOS ONE 7, e51493 (2012).
14. T. Zhu, N. Wang, A. Carr, D. S. Nam, R. Moor-Jankowski, D. A. Cooper, D. D. Ho, Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70, 3098-3107 (1996).
15. D. Kolodkin-Gal, S. L. Hulot, B. Korioth-Schmitz, R. B. Gombos, Y. Zheng, J. Owuor, M. A. Lifton, C. Ayeni, R. M. Najarian, W. W. Yeh, M. Asmal, G. Zamir, N. L. Letvin, Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 87, 13589-13597 (2013).
16. B. Sallé, P. Brochard, O. Bourry, A. Mannioui, T. Andrieu, S. Prevot, N. Dejucq-Rainsford, N. Dereuddre-Bosquet, R. Le Grand, Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 202, 337-344 (2010).
17. A. M. Weiler, Q. Li, L. Duan, M. Kaizu, K. L. Weisgrau, T. C. Friedrich, M. R. Reynolds, A. T. Haase, E. G. Rakasz, Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J. Virol. 82, 4154-4158 (2008).
18. I. A. Abela, L. Berlinger, M. Schanz, L. Reynell, H. F. Günthard, P. Rusert, A. Trkola, Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLOS Pathog. 8, e1002634 (2012).
19. C. J. A. Duncan, J. P. Williams, T. Schiffner, K. Gärtner, C. Ochsenbauer, J. Kappes, R. A. Russell, J. Frater, Q. J. Sattentau, High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse. J. Virol. 88, 2025-2034 (2014).
20. R. B. Gombos, D. Kolodkin-Gal, L. Eslamizar, J. O. Owuor, E. Mazzola, A. M. Gonzalez, B. Korioth-Schmitz, R. S. Gelman, D. C. Montefiori, B. F. Haynes, J. E. Schmitz, Inhibitory effect of individual or combinations of broadly neutralizing antibodies and antiviral reagents against cell-free and cell-to-cell HIV-1 transmission. J. Virol. 89, 7813-7828 (2015).
21. T. Schiffner, Q. J. Sattentau, C. J. A. Duncan, Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. Vaccine 31, 5789-5797 (2013).
22. J.-P. Julien, D. Sok, R. Khayat, J. H. Lee, K. J. Doores, L. M. Walker, A. Ramos, D. C. Diwanji, R. Pejchal, A. Cupo, U. Katpally, R. S. Depetris, R. L. Stanfield, R. McBride, A. J. Marozsan, J. C. Paulson, R. W. Sanders, J. P. Moore, D. R. Burton, P. Poignard, A. B. Ward, I. A. Wilson, Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLOS Pathog. 9, e1003342 (2013).
23. M. Malbec, F. Porrot, R. Rua, J. Horwitz, F. Klein, A. Halper-Stromberg, J. F. Scheid, C. Eden, H. Mouquet, M. C. Nussenzweig, O. Schwartz, Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J. Exp. Med. 210, 2813-2821 (2013).
24. H. Li, C. Zony, P. Chen, B. K. Chen, Reduced potency and incomplete neutralization of broadly neutralizing antibodies against cell-to-cell transmission of HIV-1 with transmitted founder Envs. J. Virol. 91, e02425-16 (2017).
25. C.-L. Lu, D. K. Murakowski, S. Bournazos, T. Schoofs, D. Sarkar, A. Halper-Stromberg, J. A. Horwitz, L. Nogueira, J. Golijanin, A. Gazumyan, J. V. Ravetch, M. Caskey, A. K. Chakraborty, M. C. Nussenzweig, Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001-1004 (2016).
26. T. Bruel, F. Guivel-Benhassine, S. Amraoui, M. Malbec, L. Richard, K. Bourdic, D. A. Donahue, V. Lorin, N. Casartelli, N. Noël, O. Lambotte, H. Mouquet, O. Schwartz, Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 7, 10844 (2016).
27. C. D. Andrews, Y. L. Yueh, W. R. Spreen, L. St. Bernard, M. Boente-Carrera, K. Rodriguez, A. Gettie, K. Russell-Lodrigue, J. Blanchard, S. Ford, H. Mohri, C. Cheng-Mayer, Z. Hong, D. D. Ho, M. Markowitz, A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra4 (2015).
28. M. Kovarova, O. D. Council, A. A. Date, J. M. Long, T. Nochi, M. Belshan, A. Shibata, H. Vincent, C. E. Baker, W. O. Thayer, G. Kraus, S. Lachaud-Durand, P. Williams, C. J. Destache, J. V. Garcia, Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission. PLOS Pathog. 11, e1005075 (2015).
29. S. J. Kent, C. J. Dale, C. Ranasinghe, I. Stratov, R. De Rose, S. Chea, D. C. Montefiori, S. Thomson, I. A. Ramshaw, B. E. H. Coupar, D. B. Boyle, M. Law, K. M. Wilson, A. J. Ramsay, Mucosallyadministered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 23, 5009-5021 (2005).
30. C. J. Batten, R. De Rose, K. M. Wilson, M. B. Agy, S. Chea, I. Stratov, D. C. Montefiori, S. J. Kent, Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res. Hum. Retroviruses 22, 580-588 (2006).
31. S. G. Hansen, J. C. Ford, M. S. Lewis, A. B. Ventura, C. M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, A. W. Legasse, M. J. Chiuchiolo, C. L. Parks, M. K. Axthelm, J. A. Nelson, M. A. Jarvis, M. Piatak Jr., J. D. Lifson, L. J. Picker, Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
32. H. Li, S. Wang, R. Kong, W. Ding, F.-H. Lee, Z. Parker, E. Kim, G. H. Learn, P. Hahn, B. Policicchio, E. Brocca-Cofano, C. Deleage, X. Hao, G.-Y. Chuang, J. Gorman, M. Gardner, M. G. Lewis, T. Hatziioannou, S. Santra, C. Apetrei, I. Pandrea, S. M. Alam, H.-X. Liao, X. Shen, G. D. Tomaras, M. Farzan, E. Chertova, B. F. Keele, J. D. Estes, J. D. Lifson, R. W. Doms, D. C. Montefiori, B. F. Haynes, J. G. Sodroski, P. D. Kwong, B. H. Hahn, G. M. Shaw, Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 113, E3413-E3422 (2016).
33. S. G. Hansen, M. Piatak Jr., A. B. Ventura, C. M. Hughes, R. M. Gilbride, J. C. Ford, K. Oswald, R. Shoemaker, Y. Li, M. S. Lewis, A. N. Gilliam, G. Xu, N. Whizin, B. J. Burwitz, S. L. Planer, J. M. Turner, A. W. Legasse, M. K. Axthelm, J. A. Nelson, K. Früh, J. B. Sacha, J. D. Estes, B. F. Keele, P. T. Edlefsen, J. D. Lifson, L. J. Picker, Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
34. A. J. Ritchie, S. L. Campion, J. Kopycinski, Z. Moodie, Z. M. Wang, K. Pandya, S. Moore, M. K. Liu, S. Brackenridge, K. Kuldanek, K. Legg, M. S. Cohen, E. L. Delwart, B. F. Haynes, S. Fidler, A. J. McMichael, N. Goonetilleke, Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. J. Virol. 85, 3507-3516 (2011).
35. S. L. Rowland-Jones, T. Dong, L. Dorrell, G. Ogg, P. Hansasuta, P. Krausa, J. Kimani, S. Sabally, K. Ariyoshi, J. Oyugi, K. S. MacDonald, J. Bwayo, H. Whittle, F. A. Plummer, A. J. McMichael, Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol. Lett. 66, 9-14 (1999).
36. P. Balfe, S. Shapiro, M. Hsu, C. Buckner, J. M. Harouse, C. Cheng-Mayer, Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques. Virology 318, 267-279 (2004).
37. J. S. McLellan, M. Pancera, C. Carrico, J. Gorman, J.-P. Julien, R. Khayat, R. Louder, R. Pejchal, M. Sastry, K. Dai, S. O'Dell, N. Patel, S. Shahzad-ul-Hussan, Y. Yang, B. Zhang, T. Zhou, J. Zhu, J. C. Boyington, G.-Y. Chuang, D. Diwanji, I. Georgiev, Y. D. Kwon, D. Lee, M. K. Louder, S. Moquin, S. D. Schmidt, Z.-Y. Yang, M. Bonsignori, J. A. Crump, S. H. Kapiga, N. E. Sam, B. F. Haynes, D. R. Burton, W. C. Koff, L. M. Walker, S. Phogat, R. Wyatt, J. Orwenyo, L.-X. Wang, J. Arthos, C. A. Bewley, J. R. Mascola, G. J. Nabel, W. R. Schief, A. B. Ward, I. A. Wilson, P. D. Kwong, Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
38. A. Pegu, Z.-y. Yang, J. C. Boyington, L. Wu, S.-Y. Ko, S. D. Schmidt, K. McKee, W.-P. Kong, W. Shi, X. Chen, J.-P. Todd, N. L. Letvin, J. Huang, M. C. Nason, J. A. Hoxie, P. D. Kwong, M. Connors, S. S. Rao, J. R. Mascola, G. J. Nabel, Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6, 243ra88 (2014).
39. L. M. Walker, S. K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond; Protocol G Principal Investigators, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, D. R. Burton, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
40. X. Wu, T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N. S. Longo, M. Louder, K. McKee, S. O'Dell, S. Perfetto, S. D. Schmidt, W. Shi, L. Wu, Y. Yang, Z.-Y. Yang, Z. Yang, Z. Zhang, M. Bonsignori, J. A. Crump, S. H. Kapiga, N. E. Sam, B. F. Haynes, M. Simek, D. R. Burton, W. C. Koff, N. A. Doria-Rose, M. Connors; NISC Comparative Sequencing Program, J. C. Mullikin, G. J. Nabel, M. Roederer, L. Shapiro, P. D. Kwong, J. R. Mascola, Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
41. M. Bonsignori, K.-K. Hwang, X. Chen, C.-Y. Tsao, L. Morris, E. Gray, D. J. Marshall, J. A. Crump, S. H. Kapiga, N. E. Sam, F. Sinangil, M. Pancera, Y. Yongping, B. Zhang, J. Zhu, P. D. Kwong, S. O'Dell, J. R. Mascola, L. Wu, G. J. Nabel, S. Phogat, M. S. Seaman, J. F. Whitesides, M. A. Moody, G. Kelsoe, X. Yang, J. Sodroski, G. M. Shaw, D. C. Montefiori, T. B. Kepler, G. D. Tomaras, S. M. Alam, H.-X. Liao, B. F. Haynes, Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998-10009 (2011).
42. A. W. Chung, M. Ghebremichael, H. Robinson, E. Brown, I. Choi, S. Lane, A.-S. Dugast, M. K. Schoen, M. Rolland, T. J. Suscovich, A. E. Mahan, L. Liao, H. Streeck, C. Andrews, S. Rerks-Ngarm, S. Nitayaphan, M. S. de Souza, J. Kaewkungwal, P. Pitisuttithum, D. Francis, N. L. Michael, J. H. Kim, C. Bailey-Kellogg, M. E. Ackerman, G. Alter, Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6, 228ra38 (2014).
43. D. J. DiLillo, G. S. Tan, P. Palese, J. V. Ravetch, Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014).
44. S. Jegaskanda, P. C. Reading, S. J. Kent, Influenza-specific antibody-dependent cellular cytotoxicity: Toward a universal influenza vaccine. J. Immunol. 193, 469-475 (2014).
45. S. L. Gooneratne, J. Richard, W. S. Lee, A. Finzi, S. J. Kent, M. S. Parsons, Slaying the Trojan Horse: Natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells. J. Virol. 89, 97-109 (2015).
46. N. Anfossi, P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. Frassati, D. Reviron, D. Middleton, F. Romagné, S. Ugolini, E. Vivier, Human NK cell education by inhibitory receptors for MHC class I. Immunity 25, 331-342 (2006).
47. S. Lopez-Vergès, J. M. Milush, S. Pandey, V. A. York, J. Arakawa-Hoyt, H. Pircher, P. J. Norris, D. F. Nixon, L. L. Lanier, CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116, 3865-3874 (2010).
48. M. S. Parsons, L. Loh, S. Gooneratne, R. J. Center, S. J. Kent, Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation. AIDS 28, 2781-2786 (2014).
49. M. S. Parsons, K. Zipperlen, M. Gallant, M. Grant, Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. J. Leukoc. Biol. 88, 905-912 (2010).
50. B. Moldt, M. Shibata-Koyama, E. G. Rakasz, N. Schultz, Y. Kanda, D. C. Dunlop, S. L. Finstad, C. Jin, G. Landucci, M. D. Alpert, A.-S. Dugast, P. W. H. I. Parren, F. Nimmerjahn, D. T. Evans, G. Alter, D. N. Forthal, J. E. Schmitz, S. Iida, P. Poignard, D. I. Watkins, A. J. Hessell, D. R. Burton, A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86, 6189-6196 (2012).
51. C. S. Fernandez, J. C. Reece, U. Saepuloh, R. De Rose, D. Ishkandriati, D. H. O'Connor, R. W. Wiseman, S. J. Kent, Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques. Immunogenetics 63, 511-521 (2011).
52. A. Sexton, R. De Rose, J. C. Reece, S. Alcantara, L. Loh, J. M. Moffat, K. Laurie, A. Hurt, P. C. Doherty, S. J. Turner, S. J. Kent, J. Stambas, Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J. Virol. 83, 7619-7628 (2009).
53. M. S. Parsons, D. Rouleau, J.-P. Routy, R. LeBlanc, M. D. Grant, N. F. Bernard, Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. AIDS 25, 1249-1264 (2011).
54. R. J. Center, A. K. Wheatley, S. M. Campbell, A. J. Gaeguta, V. Peut, S. Alcantara, C. Siebentritt, S. J. Kent, D. F. J. Purcell, Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 27, 6605-6612 (2009).
55. H. M. Trist, P. S. Tan, B. D. Wines, P. A. Ramsland, E. Orlowski, J. Stubbs, E. E. Gardiner, G. A. Pietersz, S. J. Kent, I. Stratov, D. R. Burton, P. M. Hogarth, Polymorphisms and interspecies differences of the activating and inhibitory FcgRII of Macaca nemestrina influence the binding of human IgG subclasses. J. Immunol. 192, 792-803 (2014).
56. S. Jegaskanda, J. T. Weinfurter, T. C. Friedrich, S. J. Kent, Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87, 5512-5522 (2013).
57. A. Smalls-Mantey, N. Doria-Rose, R. Klein, A. Patamawenu, S. A. Migueles, S.-Y. Ko, C. W. Hallahan, H. Wong, B. Liu, L. You, J. Scheid, J. C. Kappes, C. Ochsenbauer, G. J. Nabel, J. R. Mascola, M. Connors, Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 86, 8672-8680 (2012).
58. J. Richard, M. Veillette, L.-A. Batraville, M. Coutu, J.-P. Chapleau, M. Bonsignori, N. Bernard, C. Tremblay, M. Roger, D. E. Kaufmann, A. Finzi, Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. J. Virol. Methods 208, 107-114 (2014).
59. B. D. Wines, H. A. Vanderven, S. E. Esparon, A. B. Kristensen, S. J. Kent, P. M. Hogarth, Dimeric FcgR ectodomains as probes of the Fc receptor function of anti-influenza virus IgG. J. Immunol. 197, 1507-1516 (2016).
60. R. D. Mason, S. Alcantara, V. Peut, L. Loh, J. D. Lifson, R. De Rose, S. J. Kent, Inactivated simian immunodeficiency virus-pulsed autologous fresh blood cells as an immunotherapy strategy. J. Virol. 83, 1501-1510 (2009).
61. M. J. Lopker, G. Q. Del Prete, J. D. Estes, H. Li, C. Reid, L. Newman, L. Lipkey, C. Camus, J. L. Easlick, S. Wang, J. M. Decker, K. J. Bar, G. Learn, R. Pal, D. E. Weiss, B. H. Hahn, J. D. Lifson, G. M. Shaw, B. F. Keele, Derivation and characterization of pathogenic transmitted/founder molecular clones from simian immunodeficiency virus SIVsmE660 and SIVmac251 following mucosal infection. J. Virol. 90, 8435-8453 (2016).
62. J. R. Francica, Z. Sheng, Z. Zhang, Y. Nishimura, M. Shingai, A. Ramesh, B. F. Keele, S. D. Schmidt, B. J. Flynn, S. Darko, R. M. Lynch, T. Yamamoto, R. Matus-Nicodemos, D. Wolinsky; NISC Comparative Sequencing Program, M. Nason, N. M. Valiante, P. Malyala, E. De Gregorio, S. W. Barnett, M. Singh, D. T. O'Hagan, R. A. Koup, J. R. Mascola, M. A. Martin, T. B. Kepler, D. C. Douek, L. Shapiro, R. A. Seder, Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nat. Commun. 6, 6565 (2015).
63. D. C. Montefiori, Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395-405 (2009).